What is in the dispatch?

New studies in people and reviews that pooled many studies, with how many people took part and how big the effect was. Studies that passed their finish date without sharing results. Pulled papers. And the details headlines drop, like what the drug was compared against and who paid. Every item has its PubMed ID or study registry number so you can check it.

Is anything being sold?

Nothing in the dispatch. No discount codes, no sponsored items and no seller picks in any issue. None of that reaches the dispatch. A study that found nothing has to be as worth printing as one that found something, or none of this is worth reading.

Where do the items come from?

A script searches PubMed and ClinicalTrials.gov for anything new on every compound in the catalogue. It puts studies in people, reviews that pooled many studies, and pulled papers first. Each record is then read at the source before it goes in an issue. Nothing gets in just because of a press release.

Can I read past issues without subscribing?

Yes. Every issue is published in full on this site as a permanent article, with its sources and links to the compound pages. The archive is below, and none of it is behind a paywall.

What changed in the evidence, every other week

Most newsletters in this field just pass on press releases. A press release is a company describing its own study before anyone can check it. That is the weakest kind of evidence that still counts as news. This one is built by searching PubMed and the study registries for all 453 compounds on this site. We read the records that come back and report them with their ID numbers attached.

That means it reports what is missing too. A large final-stage study that passed its finish date and shared no results is real news. It tells you the data exists and you cannot see it. Issue 001 is mostly about exactly that.

Every other week, on a Saturday. Your address is used for the dispatch and nothing else. One click unsubscribes. There is no email series and no sales pitch. The dispatch sells nothing.

What an issue actually contains

Studies that finished, and studies that finished without telling anyone

Every two weeks we check every compound here against ClinicalTrials.gov, the public list of registered studies. We look for anything that changed. Say a large final-stage study passed its end date and posted no results. That is news. It means the results exist and you cannot see them yet. A press release will never tell you that.

New studies in people and reviews that pool many studies, with the numbers

We search PubMed, the big library of medical papers, for every compound here. Studies in people, reviews that pool many studies, and pulled papers get read first. Each item tells you how many people were in it, how big the result was, and its ID number. So you can check it yourself instead of taking our word.

What it was compared to, the dose, and who paid

Beating a rival drug at its lowest dose is not the same as beating it at its best dose. That detail is gone by the time a result becomes a headline. We name who paid, both ways. That includes when a study found nothing and was paid for by someone who wanted it to find nothing.

Retractions and corrections, including ours

Papers get pulled, and people in this field keep quoting them for years after. When a study behind a claim on this site gets pulled or corrected, the issue says so and the page gets fixed. When we get something wrong, that goes in too.

No products in an issue

No discount codes, no paid placements, no seller picks. The site earns affiliate money, and we say so on its price rows. None of that money is tied to what an issue says. That is the only way a study that found nothing gets told as fairly as one that found something.

If two weeks pass with nothing worth your time, the issue will be two lines long and say so. Real news in this field does not show up on a schedule. A newsletter that is always exciting anyway has started making things up.

Every issue, in full, free

Issue 001Sep 12, 2026
Five Retatrutide Phase 3 Trials Have Finished And None Has Posted Results
Five big retatrutide studies covering 6,415 people have finished collecting results, and none has shared them. A CagriSema against tirzepatide study finished in July at a low tirzepatide dose that suits the company paying for it. And a review that pooled 378 studies ranked what actually prevents diabetes.
Read the issue

Questions people ask about this

What is in the dispatch?: New studies in people and reviews that pooled many studies, with how many people took part and how big the effect was. Studies that passed their finish date without sharing results. Pulled papers. And the details headlines drop, like what the drug was compared against and who paid. Every item has its PubMed ID or study registry number so you can check it.
How often does it arrive?: Every other week, on a Saturday. If two weeks pass with nothing worth your time, the issue will be short and say so. It will not pad itself out.
Is anything being sold?: Nothing in the dispatch. No discount codes, no sponsored items and no seller picks in any issue. None of that reaches the dispatch. A study that found nothing has to be as worth printing as one that found something, or none of this is worth reading.
Where do the items come from?: A script searches PubMed and ClinicalTrials.gov for anything new on every compound in the catalogue. It puts studies in people, reviews that pooled many studies, and pulled papers first. Each record is then read at the source before it goes in an issue. Nothing gets in just because of a press release.
Can I read past issues without subscribing?: Yes. Every issue is published in full on this site as a permanent article, with its sources and links to the compound pages. The archive is below, and none of it is behind a paywall.